{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T01:30:01Z","timestamp":1776303001121,"version":"3.50.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,7,1]],"date-time":"2013-07-01T00:00:00Z","timestamp":1372636800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Progress in Cardiovascular Diseases"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.pcad.2013.05.008","type":"journal-article","created":{"date-parts":[[2013,8,27]],"date-time":"2013-08-27T18:32:33Z","timestamp":1377628353000},"page":"103-108","source":"Crossref","is-referenced-by-count":14,"title":["Medical Treatment for Thoracic Aortic Aneurysm \u2013 Much More Work To Be Done"],"prefix":"10.1016","volume":"56","author":[{"given":"Andrew S.","family":"Chun","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John A.","family":"Elefteriades","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandip K.","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pcad.2013.05.008_bb0005","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.jtcvs.2007.08.047","article-title":"Recent advances in understanding Marfan syndrome: should we now treat surgical patients with losartan?","volume":"135","author":"Matt","year":"2008","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.pcad.2013.05.008_bb0010","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1161\/CIRCULATIONAHA.110.006486","article-title":"Medical therapy of thoracic aortic aneurysms. Are we there yet?","volume":"124","author":"Danyi","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2013.05.008_bb0015","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1056\/NEJM199405123301902","article-title":"Progression of aortic dilation and the benefit of long-term beta-adrenergic blockade in Marfan\u2019s syndrome","volume":"330","author":"Shores","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2013.05.008_bb0020","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0002-9149(00)80066-1","article-title":"Life expectancy in the Marfan syndrome","volume":"75","author":"Silverman","year":"1995","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2013.05.008_bb0025","doi-asserted-by":"crossref","unstructured":"Chun AS, Elefteriades JA, Mukherjee SK: Do beta-blockers really work for prevention of aortic aneurysms \u2013 Time for reassessment. AORTA June 2013. Volume 1; Issue 1.","DOI":"10.12945\/j.aorta.2013.13.002"},{"key":"10.1016\/j.pcad.2013.05.008_bb0030","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ijcard.2005.11.116","article-title":"The effect of beta-blocker therapy on clinical outcome in patients with Marfan\u2019s syndrome: a meta-analysis","volume":"114","author":"Gersony","year":"2007","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pcad.2013.05.008_bb0035","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/0002-9149(94)90762-5","article-title":"Effect of beta-adrenergic blockade on aortic root rate of dilation in the Marfan syndrome","volume":"74","author":"Salim","year":"1994","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2013.05.008_bb0040","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1136\/hrt.75.4.389","article-title":"Aortic root complications in Marfan\u2019s syndrome: identification of a lower risk group","volume":"75","author":"Legget","year":"1994","journal-title":"Heart"},{"key":"10.1016\/j.pcad.2013.05.008_bb0045","article-title":"Medical management of thoracic aortic aneurysm disease","author":"Braverman","year":"2012","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.pcad.2013.05.008_bb0050","doi-asserted-by":"crossref","first-page":"2787","DOI":"10.1056\/NEJMoa0706585","article-title":"Angiotensin II blockade and aortic-root dilation in Marfan\u2019s syndrome","volume":"358","author":"Brooke","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pcad.2013.05.008_bb0055","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1126\/science.1124287","article-title":"Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome","volume":"312","author":"Habashi","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.pcad.2013.05.008_bb0060","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ajmg.a.34386","article-title":"The 8th International Research Symposium on Marfan syndrome and related conditions","volume":"158A","author":"Pyeritz","year":"2012","journal-title":"Am J Med Genet A"},{"key":"10.1016\/j.pcad.2013.05.008_bb0065","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1038\/nature10145","article-title":"Lessons on the pathogenesis of aneurysm from heritable conditions","volume":"473","author":"Lindsay","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.pcad.2013.05.008_bb0070","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.pharmthera.2011.04.002","article-title":"The role of the renin-angiotensin system in thoracic aortic aneurysms: clinical implications","volume":"131","author":"Moltzer","year":"2011","journal-title":"Pharm Ther"},{"key":"10.1016\/j.pcad.2013.05.008_bb0075","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.acvd.2010.04.008","article-title":"Rationale and design of a randomized clinical trial (Marfan Sartan) of angiotensin II receptor blocker therapy versus placebo in individuals with Marfan syndrome","volume":"103","author":"Detaint","year":"2010","journal-title":"Arch Cardiovasc Dis"},{"key":"10.1016\/j.pcad.2013.05.008_bb0080","doi-asserted-by":"crossref","first-page":"354","DOI":"10.2459\/JCM.0b013e3283232a45","article-title":"Rationale and design of a trial evaluating the effects of losartan vs. nebivolol vs. the association of both on the progression of aortic root dilation in Marfan syndrome with FBN1 gene mutations","volume":"10","author":"Gambarin","year":"2009","journal-title":"J Cardiovasc Med"},{"key":"10.1016\/j.pcad.2013.05.008_bb0085","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jvs.2007.09.016","article-title":"Doxycycline delays aneurysm rupture in a mouse model of Marfan syndrome","volume":"47","author":"Xiong","year":"2008","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.pcad.2013.05.008_bb0090","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1161\/CIRCRESAHA.108.174367","article-title":"Long-term doxycycline is more effective than atenolol to prevent thoracic aortic aneurysm in Marfan syndrome through the inhibition of matrix metalloproteinase-2 and \u22129","volume":"102","author":"Chung","year":"2008","journal-title":"Circ Res"},{"key":"10.1016\/j.pcad.2013.05.008_bb0095","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1161\/CIRCULATIONAHA.108.806505","article-title":"Clinical trial of doxycycline for matrix metalloproteinase-9 inhibition in patients with an abdominal aneurysm: doxycycline selectively depletes aortic wall neutrophils and cytotoxic T cells","volume":"119","author":"Lindeman","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.pcad.2013.05.008_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1067\/mva.2002.125018","article-title":"Prolonged administration of doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a prospective (Phase II) multicenter study","volume":"36","author":"Baxter","year":"2002","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.pcad.2013.05.008_bb0105","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1067\/mva.2001.117891","article-title":"Use of doxycycline to decrease the growth rate of abdominal aortic aneurysms: a randomized, double-blind, placebo-controlled pilot study","volume":"34","author":"Mosorin","year":"2001","journal-title":"J Vasc Surg"},{"key":"10.1016\/j.pcad.2013.05.008_bb0110","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jacc.2009.08.084","article-title":"Thoracic aortic aneurysm: clinically pertinent controversies and uncertainties","volume":"55","author":"Elefteriades","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pcad.2013.05.008_bb0115","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/j.jtcvs.2011.08.043","article-title":"Matrix metalloproteinase 14 and 19 expression is associated with thoracic aortic aneurysms","volume":"144","author":"Jackson","year":"2012","journal-title":"J Thorac Cardiovasc Surg"},{"key":"10.1016\/j.pcad.2013.05.008_bb0120","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/j.athoracsur.2004.05.088","article-title":"Increased tissue microarray matrix metalloproteinase expression favors proteolysis in thoracic aortic aneurysms and dissections","volume":"78","author":"Koullias","year":"2004","journal-title":"Ann Thorac Surg"},{"issue":"7","key":"10.1016\/j.pcad.2013.05.008_bb0125","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.amjcard.2011.11.038","article-title":"Comparison of the effect of the long-term outcomes in patients with thoracic aortic aneurysm of taking versus not taking a statin drug","volume":"109","author":"Jovin","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pcad.2013.05.008_bb0130","unstructured":"Stein LH, Berger J, Tranquilli M. et al. Statin therapy and the natural history of thoracic aortic aneurysm. In press, American Journal of Cardiology."},{"issue":"5","key":"10.1016\/j.pcad.2013.05.008_bb0135","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1161\/01.ATV.0000068646.76823.AE","article-title":"Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages","volume":"23","author":"Luan","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"}],"container-title":["Progress in Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062013001084?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0033062013001084?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T05:08:49Z","timestamp":1563772129000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0033062013001084"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S0033062013001084"],"URL":"https:\/\/doi.org\/10.1016\/j.pcad.2013.05.008","relation":{},"ISSN":["0033-0620"],"issn-type":[{"value":"0033-0620","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]}}}